

## SUPPLEMENTARY DATA

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Ryhänen S, Häkkinen T, Siljander H, et al. Impact of Intranasal Insulin on Insulin AntibodyAffinity and Isotypes In Young Children with HLA-Conferred Susceptibility to Type 1 Diabetes. *Diabetes Care*

**Supplementary Table 1.** Comparison of baseline characteristics of the study subjects in the intervention arm of DIPP (*Näntö-Salonen et al. Lancet 372:1746-1755, 2008*) and in present study.

	Intervention arm of DIPP		Manuscript DC10-1449	
	insulin	placebo	insulin	placebo
Average age, years	2.8	2.7	3.3	3.2
Average IAA level, RU	6.0	7.7	9.8	11.3
High-risk HLA genotype	36%	34%	27%	36%
Moderate-risk HLA genotype	64%	66%	73%	64%

## SUPPLEMENTARY DATA

**Supplementary Table 2.** Baseline characteristics of the study subjects.

	Placebo group	Insulin group	All subjects
n	47	48	95
Age, years, mean (range)	3.2 (1.0 – 7.8)	3.3 (1.22 – 9.2)	3.3 (1.0 – 9.2)
Sex, males (%)	28 (59.6%)	28 (58.3%)	56 (58.9%)
Autoantibody positivity			
ICA, n (%)	47 (100)	48 (100)	95 (100)
IAA, n (%)	42 (89.4)	45 (93.8)	87 (91.6)
GADA, n (%)	33 (70.2)	36 (75.0)	69 (72.6)
IA-2A, n (%)	32 (68.1)	31 (64.6)	63 (66.3)
Autoantibody levels			
ICA, JDF units, median (range)	44 (3 – 1742)	26 (3 – 640)	33 (3 – 1742)
IAA, RU, median (range)	11.3 (1.4 – 293.3)	9.8 (0.7 – 166.0)	11.0 (0.7 – 293.3)
GADA, RU, median (range)	13.8 (0.0 – 776.6)	25.5 (0.1 – 224.0)	17.0 (0.0 – 776.6)
IA-2A, RU, median (range)	16.7 (0.1 – 135.8)	2.4 (0.0 – 133.9)	13.5 (0.0 – 135.8)

## SUPPLEMENTARY DATA

**Supplementary Table 3.** Comparison of baseline characteristics of the study subjects testing positive for IgG3 in at least one of the three samples obtained before the start of the treatment and 3 and 6 months later.

	Placebo group	Insulin group	All subjects
n	14	19	33
Age, years, mean (range)	1.9 (1.1 – 3.6)	2.4 (1.3 – 4.4)	2.2 (1.2 – 4.4)
Sex. males (%)	5 (35.7)	8 (42.1)	13 (39.4)
Autoantibody positivity			
ICA, n (%)	14 (100)	19 (100)	33 (100)
IAA, n (%)	14 (100)	19 (100)	33 (100)
GADA, n (%)	12 (85.7)	17 (89.5)	29 (87.9)
IA-2A, n (%)	10 (71.4)	13 (68.4)	23 (69.7)
Autoantibody levels			
ICA, JDF units, median (range)	135 (7 – 515)	121 (7 – 640)	127 (7 – 640)
IAA, RU, median (range)	71.3 (11.0 – 293.3)	33.0 (5.9 – 166.0)	49.2 (5.9 – 293.3)
GADA, RU, median (range)	44.5 (0.3 – 192.4)	82.1 (0.2 – 224.0)	66.1 (0.2 – 224.0)
IA-2A, RU, median (range)	36.3 (0.1 – 135.8)	35.3 (0.0 – 133.9)	35.7 (0.0 – 135.8)
HLA risk group			
High-risk HLA genotype, n (%)	4 (28.6)	3 (15.8)	7 (21.2)
Moderate-risk HLA genotype, n (%)	10 (71.4)	16 (84.2)	26 (78.8)